PPCB Propanc Biopharma Inc

A clinical start date is one milestone. The work required to reach it happens long before. At $PPCB, GMP manufacturing is underway, raw drug substance supply is secured, PK method validation has commenced, and regulatory documentation is advancing toward the planned November HREC submission. Across biotech, companies such as $RCKT in rare cardiovascular disease and $DTIL in Duchenne muscular dystrophy are advancing through their own clinical development paths. Different diseases require different science, but execution is what moves programs forward. For PRP, that work is advancing today toward the targeted February 2027 Phase 1b First-In-Human study. Each milestone brings PRP one step closer to clinical evaluation.

$PPCB this company needs some PR to plug this bleeding! This has been an incredibly painful bleed for a couple weeks now. It doesn’t appear there is anyone working in their investor relations department right now 😂. With such a small float, anyone that wants to $100K worth would spike this quick and possibly trigger a squeeze. Standing by…….

$PPCB I may just wait to short this once they cure cancer, because the radio silence from management and no PR will definitely sink this time and time again.

PRP’s path to the clinic is no longer just a development plan. The infrastructure behind it is taking shape. $PPCB has established key relationships supporting Phase 1b, including Avance Clinical for clinical delivery, a specialized CDMO for GMP manufacturing, and FyoniBio for PRP’s PK assay. Clinical development requires multiple pieces to come together. For PRP, those pieces are now being put in place. The foundation for the next stage is being built now. $IONS $BEAM

$PPCB is advancing multiple workstreams in parallel to support PRP’s move into the clinic. GMP manufacturing is underway. Raw drug substance supply is secured. PK method validation has commenced. Regulatory documentation is being prepared ahead of the planned November HREC submission. Across biotech, different technologies are following their own paths toward patients—from mRNA-based medicines at $MRNA to gene-editing approaches at $CRSP. For PRP, the work behind Phase 1b is already underway.

$PPCB Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

$PPCB Dumpster fire :)) Their AI just said : "During FY2026, $PPCB raised $7.5M in gross proceeds. Since June 30, the Company has received an additional $2M through its Series C facility, which the Company expects to support planned R&D activities," From WHO's money? From dilution since they have zero revenue. Dilution = they sell some paper [promises] to you and then take THE SAME paper and sell it to somebody else also. | Claiming that: don't worry, all of you are lucky! :)) And it's not even actually "TRUE", it's fraud. It's like this: FORM 10-K | For the fiscal year ended June 30, 2026 "Repurchase Plan Between July 2026 and August 2026, the Company repurchased 320,031 shares of its common stock under the Repurchase Plan for an aggregate purchase price of approximately $500,000, at an average purchase price of $1.56 per share." next paragraph: "Shares issued for services On July 24, 2026, the Company issued an aggregate of 3,500,000 shares of common stock to (..) directors (..).

$PPCB low float Float: ~1.27M – 2.04M sharesShares Outstanding: ~2.28M sharesHeld by Insiders: ~46.47%Held by Institutions: ~1.37%

$PPCB Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 GLOBENEWSWIRE 7:30 AM ET 9/22/2026 New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset

$PPCB need more volume and we could get the halt up! Just need this to start trending. Tiniest float I’ve ever seen, won’t take much to launch. 🚀

$PPCB Don't be caught after the 15th October pump since their purpose is to actually dump them [not yet capable] + remain above $1 for at least 10 day after the split (they will crash it again in January with the lie of February badabum but now we know that "First Patient - April 2027", same LIE we get since 2015 month-after-month year-after-year). The split will attract the activity though don't forget that your amount of shares is also thrown in the gutters, imagine if they do 100:1, now you say: yay I got 10 shares in this $1.5 move ...from your initial 1000 =)) Best would be to short it in mass to not allow it to go too high so they can't instantly dump them and prolong some pain, some undercover manipulative rebuy from them. Whatever you see on the tape do no believe it's short, not everything is short as some old comments below claimed. You wait for a squeeze and what do you get at that level? Suurpriiise! 1,2,4 tops, you know them :)) 15th Oct. mark my prediction, let's see :D :))

$PPCB Stop wasting time with useless news updates. When are you actually going to stop dumping your shares? PPCB is the absolute worst-performing stock out of the 5,000 I watch .. your handling of this company is a complete joke !

$PPCB I am optimistic about the stock, but it just seems right now that they are recycling the same press release by comparing the same findings with a different product each week or every two weeks. I suppose to allow for a weekly press release and create the appearance that things are active and they are being diligent and proactive about keeping shareholders informed.

$PPCB Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

$PPCB Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ DaraxonrasibPreclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, differentiation-based mechanism with the clinical benchmark set by RASONQUE (daraxonrasib) GLOBENEWSWIRE 7:30 AM ET 10/7/2026

$PPCB ..they have no shame, how society allows this, they just put a disclaimer in the prospectus that you might lose all and 'that's it, they are "legal" "Shares outstanding before the offering: 9,831,116 shares of Common Stock (as of October 1, 2026) Shares outstanding after the offering: 16,331,116 shares, assuming the sale of all of the Shares."

$PPCB They tried to sell the shares they issued to themselves using today's news, whether the news was meaningful or useless. The news didn't generate the pump they were hoping for, yet they still dumped around a million shares. Absolutely desperate behavior.

$PPCB company drops the biggest PR ever just 2.5 weeks ago . Now people are complaining “ how come no PR?” Do you really think a company is supposed to make weekly statements? 🤦‍♂️🤦‍♂️

$PPCB By the time any good news emerges, they will likely have all passed away before they even get to hear it.